Immunomedics, Inc. (NASDAQ: IMMU), a clinical stage biopharmaceutical company that focuses on the treatment of cancer, presented data at the 2016 American Association for Cancer Research's annual meeting.
Immunomedics said in a corresponding press release that its presentation focused on the results of a Phase 1 study. Specifically, the company's IMMU-114 was shown to be superior to anti-CD20 therapy using rituximab. In addition, IMMU-114 also achieved a significant survival benefit in an animal model of human acute lymphoblastic leukemia (ALL) that is refractory to doxorubicin.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
"These data demonstrate IMMU-114's overall activity in diverse hematopoietic cancers and provide the rationale for continued clinical and preclinical evaluation alone and combined with current chemotherapeutic agents that are active in their respective indications," commented Cynthia L. Sullivan, President and Chief Executive Officer.
In a separate presentation, Immunomedics provided preclinical data for sacituzumab govitecan, the company's lead antibody-drug conjugate (ADC) for solid cancer therapy. The drug showed a "synergistic effect" when combined with olaparib, a polymerase inhibitor, as well as additive therapeutic results with microtubule inhibitors.
Despite the encouraging data, shares of Immunomedics were trading nearly flat at $2.86 early Monday afternoon. After opening for trading at $2.95, shares quickly rose to $3.00 but then gave up most of gains.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.